In summary, CD47 expression levels, SIRPα expression levels, tumor-infiltrating immune cells, immune checkpoint expression levels, and TMB are potential biomarkers that can help predict response to CD47-targeted therapy. The gene discussed is SIRPA; the disease is neoplasm.